Dr David L. Porter Explains Variations in CAR-T Cell Trial Criteria

Video

The criteria to enroll cancer patients in a clinical trial of CAR-T cells vary according to their disease, past therapy, and how far along they are in different treatments, said David L. Porter, MD, of the University of Pennsylvania Health System.

The criteria to enroll cancer patients in a clinical trial of CAR-T cells vary according to their disease, past therapy, and how far along they are in different treatments, said David L. Porter, MD, of the University of Pennsylvania Health System.

Transcript (slightly modified)

What are the criteria to enroll patients in a CAR-T cells clinical trial?

So there are a number of different CAR-T cells trials, and the criteria vary according to the patient’s disease, the actual trial that is ongoing. Right now, most CAR-T cells trials are really in the early- to mid-stage of development, and it is primarily for patients who have advanced disease who have largely been through many other different therapies and they’re not working. So it’s for patients who are running out of treatment options.

That said, we’ve been doing this now for, gosh, over 6 years, and have learned a lot more about where it’s effective, when it works, when it might not work, and in fact what a lot of the side effects are and how to manage them. Now that we know that, and we understand the side effects and the safety issues, some of the trials are starting to treat patients earlier in the course of their disease. And the criteria there are obviously very different, they’re not just for somebody who’s failed every other treatment.

So it really will vary according to somebody’s past therapy, it will vary according to their disease, and how far along they are in the different treatments.

Recent Videos
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.